McLaughlin Institute

Jeff B. Carroll, Ph.D.

Affiliate Professor

Phone:  (360) 650-2928
Email Jeff Carroll

 

 

 

 

 

 

 

 

 

 

Education

University of British Columbia, BSc, 2004, Biology
University of British Columbia, PhD, 2010, Neuroscience

 

Positions

2010-2011 Postdoctoral Fellowship, Neurology, Harvard Medical School
2011-2012 Visiting Faculty, Department of Psychology, Behavioral Neuroscience Program, WWU
2012-2016 Assistant Professor, Department of Psychology, Behavioral Neuroscience Program, WWU
2016-Present Associate Professor, Department of Psychology, Behavioral Neuroscience Program, WWU

 

Research Summary

Work in the Carroll lab is focused on  understanding the systemic effects of Huntington’s Disease, especially metabolic changes, using a mouse “knock-in” model of Huntington’s Disease.  Jeff also has a long-standing interest in gene silencing approaches to HD therapeutics, particularly using antisense oligonucleotides (ASOs).  Dr. Carroll is also engaged in education efforts targeting the Huntington’s disease community, including HD Buzz, and the effects these educational efforts have on community member’s decision making.   As well as conducting research, Jeff is a member of an HD family and himself carries the mutation which causes the disease.

 

Selected Publications

Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human molecular genetics. 2007 Jul 5;16(18):2187-98.
Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM. Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 2008 Jan 1;39(1):32-9.
 
Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Molecular Therapy. 2011 Dec 1;19(12):2178-85.
Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of disease. 2011 Jul 31;43(1):257-65.
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington’s disease. The Lancet Neurology. 2015 Nov 1;14(11):1135-42.
Bragg RM, Coffey SR, Weston RM, Ament SA, Cantle JP, Minnig S, Funk CC, Shuttleworth DD, Woods EL, Sullivan BR, Jones L, Glickenhaus A, Anderson JS, Anderson MD, Dunnett SB, Wheeler VC, MacDonald ME, Brooks SP, Price ND, Carroll JB. Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6. Htt/+ Q111/+ model of Huntington’s disease. Scientific Reports. 2017 Feb 8;7:41570.
Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR, Bergey DE, Wheeler VC, MacDonald ME, Baliga NS, Rosinski J, Hood LE, Carroll JB, Price ND. Transcriptional regulatory networks underlying gene expression changes in Huntington’s disease. Molecular systems biology. 2018 Mar 1;14(3):e7435.
Minnig S, Bragg RM, Tiwana HS, Solem WT, Hovander WS, Vik EM, Hamilton M, Legg SR, Shuttleworth DD, Coffey SR, Cantle JP, Carroll JB. Early Detection of Apathetic Phenotypes in Huntington’s Disease Knock-in Mice Using Open Source Tools. Scientific reports. 2018 Feb 2;8(1):2304.
Updated Publication Lists –

 

  • Recent Posts
  • Archives
  • Zoom in Regular Zoom out
 
Support MRI FACEBOOK Charity Navigator

© 2012-2018 McLaughlin Research Institute of Biomedical Sciences - All Rights Reserved
Site Designed and Developed by Shortgrass Web Development